Athera Biotechnologies AB, a Karolinska Development AB portfolio company, has transferred rights to the recombinant Annexin A5 to Medirista AB, the original innovator of the project. Medirista AB now holds the patent portfolio along with key preclinical assets. Athera will focus on the development of its lead product candidate, a fully human antibody in atherosclerosis.   Recombinant Annexin A5 is being developed as a potential anti-inflammatory therapy, primarily targeting prevention of complic...